In yesterday’s Wall Street session, Acorda Therapeutics Inc. (NASDAQ:ACOR) shares traded at $0.81, down -18.73% from the previous session.
1 analysts cover Acorda Therapeutics Inc. (NASDAQ:ACOR), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $1.00, this indicates a potential upside of 900.0 percent. ACOR stock price is now -8.13% away from the 50-day moving average and 38.99% away from the 200-day moving average. The market capitalization of the company currently stands at $19.52M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 1. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target enhanced from $5 to $10, H.C. Wainwright Upgraded its rating from Neutral to Buy for Acorda Therapeutics Inc. (NASDAQ: ACOR). On August 14, 2019, H.C. Wainwright Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $31 to quote $6, while ‘Wedbush’ rates the stock as ‘Neutral’.
In other news, COHEN RON, President and CEO sold 2,289 shares of the company’s stock on Mar 17. The stock was sold for $3,895 at an average price of $1.70. Upon completion of the transaction, the President and CEO now directly owns 129,601 shares in the company, valued at $0.1 million. Insiders disposed of 5,311 shares of company stock worth roughly $4301.91 over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACOR stock. A new stake in Acorda Therapeutics Inc. shares was purchased by TELEMETRY INVESTMENTS, L.L.C. during the first quarter worth $108,000. DEUTSCHE BANK AG invested $28,000 in shares of ACOR during the first quarter. In the first quarter, GROUP ONE TRADING, L.P. acquired a new stake in Acorda Therapeutics Inc. valued at approximately $8,000. In total, there are 43 active investors with 25.80% ownership of the company’s stock.
On Thursday morning Acorda Therapeutics Inc. (NASDAQ: ACOR) stock kicked off with the opening price of $1.0500. During the past 12 months, Acorda Therapeutics Inc. has had a low of $0.26 and a high of $2.29. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.70, and a quick ratio of 1.30. The fifty day moving average price for ACOR is $0.8850 and a two-hundred day moving average price translates $0.5850 for the stock.
The latest earnings results from Acorda Therapeutics Inc. (NASDAQ: ACOR) was released for Sep, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$1.43, beating analysts’ expectations of -$1.56 by 0.13. This compares to -$2.43 EPS in the same period last year. The net profit margin was -85.10% and return on equity was -95.50% for ACOR. The company reported revenue of $33.51 million for the quarter, compared to $31.46 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 6.53 percent. For the current quarter, analysts expect ACOR to generate $36.97M in revenue.
Acorda Therapeutics Inc.(ACOR) Company Profile
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson’s disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
